GATC Health Featured in Citeline’s Prestigious Scrip Asks Series on AI and Operational Excellence

“Scrip Asks… What Does 2026 Hold For Biopharma? Part 5: AI And Operational Excellence“

Irvine, CA—February 13, 2026 – GATC Health Corp, a leader in AI‑driven analytics for drug development and risk assessment, announced today its inclusion in Citeline’s “Scrip Asks… What Does 2026 Hold For Biopharma? Part 5: AI And Operational Excellence,” a feature that brings together executives and experts from leading biopharma and life sciences organizations to share perspectives on how artificial intelligence is reshaping the sector. Appearing alongside other prominent companies in the article, GATC Health is positioned as a peer contributor to the industry’s strategic dialogue on AI, digital transformation, and operational excellence.

In the Citeline feature, industry leaders describe AI as being at a turning point in biopharma, moving from experimental pilots to embedded capabilities that influence core decision making, portfolio prioritization, and operational performance. Within this context, GATC Health’s participation underscores the company’s unique focus on using AI not only as a scientific engine, but also as a financial and strategic decision-support tool across the drug development lifecycle.

“Being included in Citeline’s 2026 biopharma outlook affirms that AI is no longer optional for companies seeking to compete globally on innovation, capital efficiency, and speed to market,” said Jayson Uffens, CTO and Chairman of GATC Health. “Our Derisq™ AI report is specifically designed to help R&D and corporate teams decide which assets to advance, how to design smarter trials, and where to allocate capital for the greatest clinical and financial impact.”

GATC Health’s Operon™ AI platform integrates biological, clinical, and real-world data with financial and operational parameters to guide critical choices such as target selection, indication expansion, and portfolio optimization. By modeling risk–return profiles and probability of success at each stage, GATC enables sponsors and partners to make more informed investment decisions, reduce late-stage failure risk, and align development strategies with commercial and payer realities.

As highlighted in the article, 2026 is expected to be a pivotal year in which organizational readiness, data infrastructure, and operating discipline will determine whether companies translate AI potential into measurable outcomes. GATC Health is addressing this need by delivering decision-support tools that can be embedded into existing governance, pipeline review, and budgeting processes, helping organizations move from one-off AI experiments to repeatable, scalable value creation.

“Our mission is to close the gap between scientific promise and economic viability in drug development,” added Uffens. “By bringing together deep biological insights and rigorous financial analytics in a single AI framework, we help our partners design programs that are not only more likely to work, but also more likely to make sense for patients, payers, and shareholders.”

With its inclusion in Citeline’s “Scrip Asks” 2026 biopharma outlook, GATC Health joins a cohort of companies that are setting the pace for AI adoption and operational excellence across the global life sciences industry. The company plans to expand its collaborations with biopharma, investors, and healthcare stakeholders seeking to deploy AI as a strategic lever for higher-value, lower-risk drug development.

About GATC Health
GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health’s risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s AI platform, Operon™, is generative, creating intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide.